Cognition Therapeutics (Cognition Therapeutics) Operating Cash Flow per Share : $-0.65 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics Operating Cash Flow per Share?

Cognition Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was $-0.22. Cognition Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.65.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -49.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Cognition Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

CGTX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -75.5 Med: -62.25 Max: -49
Current: -49

During the past 5 years, Cognition Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -49.00% per year. The lowest was -75.50% per year. And the median was -62.25% per year.

CGTX's 3-Year OCF Growth Rate is ranked worse than
88.82% of 1234 companies
in the Biotechnology industry
Industry Median: 3.5 vs CGTX: -49.00

Cognition Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Cognition Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics Operating Cash Flow per Share Chart

Cognition Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.15

-0.16

-0.70

-0.78

-0.53

Cognition Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial													-0.09	-0.13	-0.14	-0.18	-0.22

Competitive Comparison of Cognition Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Cognition Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognition Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cognition Therapeutics's Price-to-Operating-Cash-Flow falls into.

Cognition Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Cognition Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-16.018	/	30.029
	=	-0.53

Cognition Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-7.244	/	33.735
	=	-0.21

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65

Cognition Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognition Therapeutics (Cognition Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2500 Westchester Avenue, Purchase, NY, USA, 10577

Website

https://www.cogrx.com

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Executives

John Brendan Doyle	officer: Chief Financial Officer	C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Lisa Ricciardi	director, officer: CEO & President	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Anthony Caggiano	officer: Chief Medical Officer	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone	director	C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace	director	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107